Search results for "bolus"

showing 10 items of 125 documents

Effects of levodopa oral bolus on the kinematics of the pointing movements in Parkinson's disease patients.

2005

We studied the time-course of a levodopa oral bolus effects on the kinematics of patients affected by a mild akinetic-rigid form of idiopathic Parkinson's disease (PD). Eleven PD patients were evaluated: a) in OFF-state, that is before their first medication or after its withdrawal, b) in ON-state, that is at 1/2, 1, 2, 3, 4, 5, 6, 24, 30 and 48 hours after the administration of 250 mg of levodopa plus 25mg of carbidopa. The main kinematics (i. e.movement time, peak of velocity, peak of acceleration and peak of deceleration) of pointing movements to six target-stimuli placed on the horizontal plane of a table were recorded. Clinical conditions were assessed according to the Motor Examinatio…

AdultMaleLevodopamedicine.medical_specialtyTime FactorsNeurologyParkinson's diseaseAdministration Oralparkinson's diesease clinical neurophysiology kinematicsKinematicsClinical neurophysiologyAntiparkinson AgentsLevodopaCentral nervous system diseaseBolus (medicine)Internal medicinemedicineHumansAgedbusiness.industryParkinson DiseaseMiddle Agedmedicine.diseaseBiomechanical PhenomenaSurgeryNeurologyCarbidopaCardiologyFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessPsychomotor Performancemedicine.drug
researchProduct

Propofol sedation administered by cardiologists without assisted ventilation for long cardiac interventions: an assessment of 1000 consecutive patien…

2011

Aims Patients can expect a cure from atrial fibrillation (AF) with ablation. Procedural safety and success depend on patient comfort, compliance, and immobility. This is difficult to achieve with benzodiazepine and opiate boluses that are the mainstay of current practice. We sought to determine the safety and efficacy of propofol infusion sedation administered to patients without assisted ventilation for AF ablation. Methods and results Procedural data from 1000 consecutive patients undergoing AF ablation were analysed. Sedation with 2% propofol was used in all procedures without assisted ventilation and was administered, monitored, and controlled by electrophysiologists. Primary outcome me…

Malemedicine.drug_classMidazolamSedationCohort StudiesBolus (medicine)Physiology (medical)Atrial FibrillationmedicineHumansAdverse effectPropofolAgedbusiness.industryPericardiocentesisAtrial fibrillationSialorrheaMiddle Agedmedicine.diseaseCardiac TamponadeTreatment OutcomeBlood pressureAnesthesiaSedativeCatheter AblationMidazolamFemaleDeep SedationHypotensionmedicine.symptomRespiratory InsufficiencyCardiology and Cardiovascular MedicinebusinessPropofolAnesthetics Intravenousmedicine.drugEuropace
researchProduct

Argatroban for elective percutaneous coronary intervention: The ARG-E04 multi-center study

2011

The synthetic arginine-derived direct thrombin inhibitor argatroban is an attractive anticoagulant for percutaneous coronary intervention (PCI), because of its rapid onset and offset, and its hepatic elimination. Argatroban was approved for PCI in patients with heparin-induced thrombocytopenia (HIT). However, there are limited data about argatroban in non-HIT patients. The objective of this open-label, multiple-dose, controlled study was to examine the safety and efficacy of argatroban in patients undergoing elective PCI.Of 140 patients randomized to three argatroban dose groups (ARG250, ARG300, and ARG350 with 250, 300, or 350 μg/kg bolus, followed by 15, 20, or 25 μg/kg/min infusion) and …

Malemedicine.drug_classmedicine.medical_treatmentActivated clotting timeHemorrhageArginineAntithrombinsArgatrobanBolus (medicine)medicineHumansAngina UnstableMyocardial infarctionAngioplasty Balloon CoronaryBlood CoagulationAgedSulfonamidesDose-Response Relationship Drugmedicine.diagnostic_testHeparinbusiness.industryAnticoagulantAnticoagulantsPercutaneous coronary interventionThrombosisMiddle Agedmedicine.diseaseDirect thrombin inhibitorPipecolic AcidsAnesthesiaConventional PCIFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up Studiesmedicine.drugInternational Journal of Cardiology
researchProduct

Estudio comparativo de la combinación de diferentes modos de administración de anestésicos locales en la analgesia del parto

2020

La analgesia epidural es una de las técnicas más demandadas y por ello dicha analgesia ha ido evolucionando en los últimos años. Recientemente se ha desarrollado el modo PIEB (Programmed Intermittent Epidural Boluses) que puede reducir el consumo de anestésico local y así minimizar consecuencias indeseables tales como la cardio o la neurotoxicidad. En el año 2012 la compañía Smiths Medical lanzó al mercado un sistema de infusión ambulatoria CADD®-Solis versión software 3.0 de la generación de bombas de infusión CADD® que permite combinar varios modos de administración del anestésico local en el espacio epidural, hasta ahora no utilizados juntos ya que no existía en el mercado una bomba con …

set standard flowepidural analgesialabor:CIENCIAS MÉDICAS [UNESCO]bolos epidurales intermitentes programadosset de flujo estandarset high flowpartoUNESCO::CIENCIAS MÉDICASanalgesia epiduralset de alto flujoprogrammed intermittent epidural bolusinfusión continua
researchProduct

A Negative FFR (Intracoronary Adenosine Bolus)

2016

This case describes the assessment of FFR for a single intermediate stenosis in the mid LAD. Since the procedure was performed using a radial access, and given the history of asthma, we preferred to use intracoronary adenosine as the vasodilator of choice. A first bolus of 50 μg was given, followed by a second one of 140 μg. The FFR was reproducible at 0.93, demonstrating that the stenosis was not relevant from the hemodynamic perspective.

medicine.medical_specialtybusiness.industryHemodynamicsVasodilationmedicine.diseaseAdenosineStenosisBolus (medicine)Internal medicinemedicineCardiologybusinessAsthmamedicine.drug
researchProduct

Inter-individual retronasal aroma release variability during cheese consumption: Role of food oral processing

2014

The aim of our study was to explain inter-individual differences on in vivo aroma release during cheese consumption by oral physiological parameters. To reach this objective, 34 subjects were recruited. Their salivary flow, oral volume and velum opening were determined. Six cheddar-based melted cheeses with different fat levels and firmness were flavoured with nonan-2-one.(NO) and ethyl propanoate (EP). During their consumption (free protocol), in vivo retro nasal aroma release was followed by Atmospheric Pressure Chemical lonisation-Mass Spectrometry (APCI-MS). Chewing activity was evaluated by electromyography recordings. Bolus saliva content, mouth-coating, and bolus rheology were also d…

Salivainter individual variability030309 nutrition & dieteticsFat content[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionFood consumption03 medical and health scienceschemistry.chemical_compound0404 agricultural biotechnologyBolus (medicine)[SDV.IDA]Life Sciences [q-bio]/Food engineeringin vivo aroma releaseAroma compoundFood scienceAromaNo release2. Zero hunger0303 health sciencesfood oral processingbiologyChemistry[ SDV.IDA ] Life Sciences [q-bio]/Food engineeringEthyl propanoatefood and beverages04 agricultural and veterinary sciencesbiology.organism_classification040401 food sciencemouth coating[SDV.AEN]Life Sciences [q-bio]/Food and Nutritionmodel cheesesFood Sciencechewing activity
researchProduct

Effects of Caffeine as an Adjuvant to Morphine in Advanced Cancer Patients

2001

Psychomotor abnormalities are one of the complications of opioid therapy in advanced cancer patients. Caffeine has potential properties to counteract the central effects of morphine. Twelve patients receiving stable doses of slow release morphine with adequate pain relief were scheduled for this double-blind placebo-controlled crossover trial. The treatment consisted of an intravenous dose of 1/6 of the daily morphine dose, using an intravenous/oral conversion ratio of 1:3. The dose calculated was administered in 5 minutes. Patients were randomly divided to received in a double-blind manner an infusion of 200 mg of caffeine or saline solution intravenously over one hour. A crossover took pl…

business.industryPlacebo-controlled studyPlaceboCrossover studychemistry.chemical_compoundAnesthesiology and Pain MedicineBolus (medicine)chemistryOpioidAnesthesiamedicineMorphineNeurology (clinical)CaffeineCancer painbusinessGeneral Nursingmedicine.drugJournal of Pain and Symptom Management
researchProduct

The impact of mastication, salivation and food bolus formation on salt release during bread consumption

2014

Health authorities recommend higher fibre and lower salt content in bread products. However, these basic ingredients of bread composition are multifunctional, and important changes in their content influence the texture, flavour and acceptability of the product. This study was designed to investigate the link between oral processing, bolus formation and sodium release during the consumption of four different breads that varied in composition and structure. Chewing behaviour was determined by surface electromyography, and salivation was quantified from the water content of the boluses collected. The kinetics of bread degradation during food bolus formation was characterised by measuring the …

AdultMaleSalivaSalt contentSodium[ SDV.AEN ] Life Sciences [q-bio]/Food and Nutritionchemistry.chemical_elementPERIODONTAL MECHANORECEPTORSBolus (medicine)Food bolus[SDV.IDA]Life Sciences [q-bio]/Food engineeringGLYCEMIC LOADHumansCORONARY-HEART-DISEASEFood scienceSodium Chloride DietarySalivaMasticationPARTICLE-SIZE DISTRIBUTIONCARBOHYDRATE INTAKEdigestive oral and skin physiologyPAROTSECRETION[ SDV.IDA ] Life Sciences [q-bio]/Food engineeringGeneral MedicineBreadMECHANICAL-PROPERTIESMiddle AgedCoronary heart diseaseMasticatory forceDeglutitionCHEWING BEHAVIORWHEAT BREADchemistrySODIUM RELEASETasteMasticationFemaleSalivation[SDV.AEN]Life Sciences [q-bio]/Food and NutritionFood Science
researchProduct

Paradoxical embolism through a patent foramen ovale from central venous catheter thrombosis: A potential cause of stroke

2020

Paradoxical embolism refers to a potential condition in which an embolus arising from a venous source crosses into the systemic circulation through a right-to-left cardiac shunt causing an arterial embolism. A 39-year-old woman carrier of a central venous catheter (CVC) without evident risk factors for stroke, developed an acute right homonymous hemianopia during hemodialysis. On neuroimaging, an infarct in the territory of the left posterior cerebral artery was demonstrated. Transesophageal echocardiography revealed a patent foramen ovale (PFO) and a large fluctuating thrombus in the right atrium on the tip of the CVC, thus allowing a diagnosis of ischemic stroke from paradoxical embolism.…

Adultmedicine.medical_specialtyArterial embolismCardioembolismmedicine.medical_treatmentEmbolismForamen Ovale Patent03 medical and health sciences0302 clinical medicineParadoxical embolismEmbolusUpper Extremity Deep Vein ThrombosisInternal medicinemedicineHumanscardiovascular diseases030212 general & internal medicineThrombusStrokebusiness.industryCardiac shuntmedicine.diseasePatent foramen ovaleStrokeNeurologyPatent foramen ovaleCardiologySettore MED/26 - NeurologiaFemaleNeurology (clinical)businessCentral venous catheterEchocardiography Transesophageal030217 neurology & neurosurgeryCentral venous catheterEmbolism ParadoxicalJournal of the Neurological Sciences
researchProduct

Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic rela…

2010

The synthetic direct thrombin inhibitor argatroban has a rapid onset and offset of anticoagulation. However, there are no data about the pharmacokinetic-pharmacodynamic (PK-PD) relationship of argatroban in patients undergoing contemporary percutaneous coronary intervention (PCI) and no data about other coagulation parameters than activated clotting time (ACT) in this setting. In the ARG-E04-trial, 140 patients were randomly assigned to argatroban (250, 300, or 350 μg/kg as bolus before PCI, followed by 15, 20, or 25 μg/kg/min infusion) or unfractionated heparin (70-100 IU/kg bolus). A 2-compartment model with first-order elimination adequately described the pharmacokinetic profile of argat…

Malemedicine.medical_treatmentActivated clotting timeArginineArgatrobanAntithrombinsBolus (medicine)PharmacokineticsmedicineHumansPharmacology (medical)Blood CoagulationAgedPharmacologySulfonamidesModels Statisticalmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryHeparinEndovascular ProceduresPercutaneous coronary interventionHeparinMiddle AgedClotting timeDirect thrombin inhibitorAnesthesiaPipecolic AcidsFemaleBlood Coagulation Testsbusinessmedicine.drugJournal of clinical pharmacology
researchProduct